It has been learned that our first national production, viagra, will be officially on the market at the end of this month. The official listing of baek yunshan kingo means that chinese pharmacists will formally participate in the distribution of the country’s huge cake against the ed drug market, thereby ending the 13-year monopoly on the ed market in china. The industry expects that, thanks to the powerful sales network and the advantages of the channels of white cloud mountain, kingo will be a star drug of between $500 million and $1 billion in the coming years。
It is known that ed (the erection functional impairment) is one of the four leading diseases in the male reproductive system, with the incidence of ed among males over 40 years of age being around 46 per cent and the incidence of ed among about 127 million patients. The nri report shows that china's potential market size would be tens of billions of yuan, assuming a price of $20/particle-60/particle for generic drugs, and five (particle)-20 times a year for ed patients receiving treatment. Currently, the ed formal treatment drugs are only $1 billion in size, and there are dozens of potential future increases。
In china, the anti-ed drug market has been monopolized by several international pharmaceutical giants, such as pfizer, renlai and bayer. According to the survey of the global pharmaceutical health consulting firm imshealth, the shares of the three foreign drugs in the chinese ed market in 2013 were 58. 8 per cent: van eko, 34. 6 per cent; and 6. 6 per cent for baier。
Following the expiration of pfizer van eicco's patent in may of this year, baek yunshan, a popular drug, submitted to the national food and drug control authority an application for registration for the production of raw materials and tablets for the production of raw materials by viaco, west timor, and, on 2 september 2014, officially obtained the production of raw materials and preparations, making it the first enterprise in the country to obtain a “viaco” birth certificate。
According to industry sources, baek yunshan jingo will break the monopoly of foreign medicine on our anti-ed market and form a positive pk for the american pfizer “vanega”, with a more “chinaized” name, more scientific dosages, channels and pro-people prices and the “father of viaco” the quality assurance that mourad directs will be its greatest advantage。
It is known that, in terms of specifications, kimgo baekyunshan is 50 mg/particle, which was developed and produced entirely on the basis of the recommended dose not used for the treatment of ed in the west of the country. The “victoria” dose is now common on the market at 100 mg. “50 mg is the recommended dose, which is sufficient for large patients. “couldn’t you say, quo jinro。
At present, the main distribution channels for “victoria” remain hospitals and retail pharmacies. According to the white cloud hills, “more than 80 per cent of the distribution channels for ed drugs are in retail pharmacies, which are one of the greatest advantages of the main baek yunshan pharmaceutical plant in comparison to foreign pharmacies, mainly for the sale of prescription drugs”. At present, the mountain of white clouds has signed cooperation agreements with a number of pharmacies in the country, including the great zhuin forest and neptune. At the hospital level, the guangzhou baek yunshan pharmaceutical plant, which is responsible for the sale of gingo, has been the leading firm for antibiotics throughout the country, with excellent channels and teams。
In terms of prices, pao yunshan states: “the sale of three types of foreign medicine currently sold in china cost more than $90-136/particle, which limits the purchasing power of some consumers. The price of jingo, on the other hand, will be significantly lower than the price of the same medicine abroad, and the price will be a major advantage for jingo.”
The journalists were also informed that dr. Feride mulad, the father of viaco, had officially been the director of the general research institute of the guangxi drug group in january 2012, and that huekshan jingo was an important achievement under the guidance of mourad. Dr. Murad stated that, in the course of the project's development, he had put forward the general requirement of international alignment to move the research forward in accordance with united states fda standards, making kingo's quality in line with original research products fully trustworthy。
Mr. Lee chugen, chairman of the guang dynamist group, said that, for the third consecutive year since 2012, the group had joined the ministry of industry and communications to champion china's pharmaceutical industry, which would combine technological, brand and channel advantages to build the gingo group. Experts expect to achieve a sales volume of $5-1 billion over the next three to five years, which will become a new profit growth point and a large variety. A combination of high value for money advantages and the “first brand of china's pharmaceutical industry” in white yunshan is expected to become the first brand of chinese ed medicine in the future。
Responsible editor: zhang dei
